nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.12.2018 | Neurotrauma (D Sandsmark, Section Editor)

A Precision Medicine Approach to Cerebral Edema and Intracranial Hypertension after Severe Traumatic Brain Injury: Quo Vadis?

verfasst von: Ruchira M. Jha, Patrick M. Kochanek

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Standard clinical protocols for treating cerebral edema and intracranial hypertension after severe TBI have remained remarkably similar over decades. Cerebral edema and intracranial hypertension are treated interchangeably when in fact intracranial pressure (ICP) is a proxy for cerebral edema but also other processes such as extent of mass lesions, hydrocephalus, or cerebral blood volume. A complex interplay of multiple molecular mechanisms results in cerebral edema after severe TBI, and these are not measured or targeted by current clinically available tools. Addressing these underpinnings may be key to preventing or treating cerebral edema and improving outcome after severe TBI.

Recent Findings

This review begins by outlining basic principles underlying the relationship between edema and ICP including the Monro-Kellie doctrine and concepts of intracranial compliance/elastance. There is a subsequent brief discussion of current guidelines for ICP monitoring/management. We then focus most of the review on an evolving precision medicine approach towards cerebral edema and intracranial hypertension after TBI. Personalization of invasive neuromonitoring parameters including ICP waveform analysis, pulse amplitude, pressure reactivity, and longitudinal trajectories are presented. This is followed by a discussion of cerebral edema subtypes (continuum of ionic/cytotoxic/vasogenic edema and progressive secondary hemorrhage). Mechanisms of potential molecular contributors to cerebral edema after TBI are reviewed. For each target, we present findings from preclinical models, and evaluate their clinical utility as biomarkers and therapeutic targets for cerebral edema reduction. This selection represents promising candidates with evidence from different research groups, overlap/inter-relatedness with other pathways, and clinical/translational potential.

Summary

We outline an evolving precision medicine and translational approach towards cerebral edema and intracranial hypertension after severe TBI.

• Stocchetti N, Carbonara M, Citerio G, Ercole A, Skrifvars MB, Smielewski P, et al. Severe traumatic brain injury: targeted management in the intensive care unit. Lancet Neurol. 2017;16:452–64 Current review on management of severe TBI in the intensive care unit. PubMedCrossRef

Stocchetti N, Maas AIR. Traumatic intracranial hypertension. N Engl J Med. 2014;370:2121–30.PubMedCrossRef

Winkler EA, Minter D, Yue JK, Manley GT. Cerebral edema in traumatic brain injury: pathophysiology and prospective therapeutic targets. Neurosurg Clin N Am. 2016;27:473–88.PubMedCrossRef

Katayama Y, Mori T, Maeda T, Kawamata T. Pathogenesis of the mass effect of cerebral contusions: rapid increase in osmolality within the contusion necrosis. Acta Neurochir Suppl. 1998;71:289–92.PubMed

Katayama Y, Kawamata T. Edema fluid accumulation within necrotic brain tissue as a cause of the mass effect of cerebral contusion in head trauma patients. Acta Neurochir Suppl (Wien). 2003;86:323–7.

Jha RM, Kochanek PM, Simard JM. Central nervous system trauma: pharmacological and therapeutic approaches. Encycl Mol Cell Biol Mol Pharmacol.

Feldmann H, Klages G, Gärtner F, Scharfenberg J. The prognostic value of intracranial pressure monitoring after severe head injuries. Acta Neurochir Suppl (Wien). 1979;28:74–7.

Feickert HJ, Drommer S, Heyer R. Severe head injury in children: impact of risk factors on outcome. J Trauma. 1999;47:33–8.PubMedCrossRef

Miller JD, Becker DP, Ward JD, Sullivan HG, Adams WE, Rosner MJ. Significance of intracranial hypertension in severe head injury. J Neurosurg. 1977;47:503–16.PubMedCrossRef

10.

Saul TG, Ducker TB. Effect of intracranial pressure monitoring and aggressive treatment on mortality in severe head injury. J Neurosurg. 1982;56:498–503.PubMedCrossRef

11.

Eisenberg HM, Gary HE, Aldrich EF, Saydjari C, Turner B, Foulkes MA, et al. Initial CT findings in 753 patients with severe head injury. A report from the NIH Traumatic Coma Data Bank. J Neurosurg. 1990;73:688–98.PubMedCrossRef

12.

Chesnut RM, Marshall LF, Klauber MR, Blunt BA, Baldwin N, Eisenberg HM, et al. The role of secondary brain injury in determining outcome from severe head injury. J Trauma. 1993;34:216–22.PubMedCrossRef

13.

Marshall LF, Smith RW, Shapiro HM. The outcome with aggressive treatment in severe head injuries. Part I: the significance of intracranial pressure monitoring. J Neurosurg. 1979;50:20–5.PubMedCrossRef

14.

Hudak AM, Peng L, Marquez de la Plata C, Thottakara J, Moore C, Harper C, et al. Cytotoxic and vasogenic cerebral oedema in traumatic brain injury: assessment with FLAIR and DWI imaging. Brain Inj. 2014;28:1602–9.PubMedCrossRef

15.

Iaccarino C, Schiavi P, Picetti E, Goldoni M, Cerasti D, Caspani M, et al. Patients with brain contusions: predictors of outcome and relationship between radiological and clinical evolution. J Neurosurg. 2014;120:908–18.PubMedCrossRef

16.

Tucker B, Aston J, Dines M, Caraman E, Yacyshyn M, McCarthy M, et al. Early brain edema is a predictor of in-hospital mortality in traumatic brain injury. J Emerg Med. 2017;53:18–29.PubMedCrossRef

17.

Vik A, Nag T, Fredriksli OA, Skandsen T, Moen KG, Schirmer-Mikalsen K, et al. Relationship of “dose” of intracranial hypertension to outcome in severe traumatic brain injury. J Neurosurg. 2008;109:678–84.PubMedCrossRef

18.

Marmarou A, Anderson RL, Ward JD, Choi SC, Young HF, Eisenberg HM, et al. Impact of ICP instability and hypotension on outcome in patients with severe head trauma. J Neurosurg. 1991;75:S59–66.CrossRef

19.

Stocchetti N, Zanaboni C, Colombo A, Citerio G, Beretta L, Ghisoni L, et al. Refractory intracranial hypertension and “second-tier” therapies in traumatic brain injury. Intensive Care Med. 2008;34:461–7.PubMedCrossRef

20.

Cooper DJ, Rosenfeld JV, Murray L, Arabi YM, Davies AR, D’Urso P, et al. Decompressive craniectomy in diffuse traumatic brain injury. N Engl J Med. 2011;364:1493–502.PubMedCrossRef

21.

• Hutchinson PJ, Kolias AG, Timofeev IS, Corteen EA, Czosnyka M, Timothy J, et al. Trial of decompressive craniectomy for traumatic intracranial hypertension. N Engl J Med. 2016;375:1119–30 Recent landmark randomized controlled trial evaluating decomrpessive craniectomy for intracranial hypertension after TBI. PubMedCrossRef

22.

Kamel H, Navi BB, Nakagawa K, Hemphill JC, Ko NU. Hypertonic saline versus mannitol for the treatment of elevated intracranial pressure: a meta-analysis of randomized clinical trials. Crit Care Med. 2011;39:554–9.PubMedCrossRef

23.

Carney N, Totten AM, O’Reilly C, Ullman JS, Hawryluk GWJ, Bell MJ, et al. Guidelines for the management of severe traumatic brain injury, fourth edition. Neurosurgery. 2017;80:6–15.PubMedCrossRef

24.

• Nielson JL, Cooper SR, Yue JK, Sorani MD, Inoue T, Yuh EL, et al. Uncovering precision phenotype-biomarker associations in traumatic brain injury using topological data analysis. PLoS One. 2017;12:e0169490 Although not focused on severe TBI, this article provides an approach towards harnessing available technologies, big data (including genetics, biomarker information), and complex phenotyping to advance precision medicine in the field. PubMedPubMedCentralCrossRef

25.

Jha RM, Kochanek PM. Adding insight to injury: a new era in neurotrauma. Lancet Neurol. 2017;16:578–80.PubMedCrossRefPubMedCentral

26.

Jha RM, Puccio AM, Chou SH-Y, Chang C-CH, Wallisch JS, Molyneaux BJ, et al. Sulfonylurea receptor-1: a novel biomarker for cerebral edema in severe traumatic brain injury. Crit Care Med. 2017;45:e255–64.PubMedPubMedCentralCrossRef

27.

Dias C, Silva MJ, Pereira E, Monteiro E, Maia I, Barbosa S, et al. Optimal cerebral perfusion pressure management at bedside: a single-center pilot study. Neurocrit Care. 2015;23:92–102.PubMedCrossRef

28.

Zeiler FA, Donnelly J, Smielewski P, Menon DK, Hutchinson PJ, Czosnyka M. Critical thresholds of intracranial pressure-derived continuous cerebrovascular reactivity indices for outcome prediction in noncraniectomized patients with traumatic brain injury. J Neurotrauma. 2018;35:1107–15.PubMedCrossRef

29.

Jha RM, Puccio AM, Okonkwo DO, Zusman BE, Wallisch JS, Shutter LA, et al. ABCC8 tag single nucleotide polymorphisms correlate with edema and outcome in traumatic brain injury. Crit Care Med. 2016;44:260.CrossRef

30.

Jha RM, Koleck TA, Puccio AM, Okonkwo DO, Park S-Y, Zusman BE, et al. Regionally clustered ABCC8 polymorphisms in a prospective cohort predict cerebral oedema and outcome in severe traumatic brain injury. J Neurol Neurosurg Psychiatry. 2018.

31.

Hutchinson PJ, Kolias AG, Czosnyka M, Kirkpatrick PJ, Pickard JD, Menon DK. Intracranial pressure monitoring in severe traumatic brain injury. BMJ. 2013;346:f1000.PubMedCrossRef

32.

Macintyre I. A hotbed of medical innovation: George Kellie (1770-1829), his colleagues at Leith and the Monro-Kellie doctrine. J Med Biogr. 2014;22:93–100.PubMedCrossRef

33.

Stern WE. Intracranial fluid dynamics: the relationship of intracranial pressure to the Monro-Kellie doctrine and the reliability of pressure assessment. J R Coll Surg Edinb. 1963;9:18–36.PubMed

34.

Marmarou A, Shulman K, Rosende RM. A nonlinear analysis of the cerebrospinal fluid system and intracranial pressure dynamics. J Neurosurg. 1978;48:332–44.PubMedCrossRef

35.

Marmarou A. A theoretical and experimental evaluation of the cerebrospinal fluid system (PhD Thesis). Philadelphia: Drexel University; 1973.

36.

Hawthorne C, Piper I. Monitoring of intracranial pressure in patients with traumatic brain injury. Front Neurol. 2014;5:121.PubMedPubMedCentralCrossRef

37.

Marmarou A, Shulman K, LaMorgese J. Compartmental analysis of compliance and outflow resistance of the cerebrospinal fluid system. J Neurosurg. 1975;43:523–34.PubMedCrossRef

38.

Chesnut R, Videtta W, Vespa P, Le Roux P. Participants in the International Multidisciplinary Consensus Conference on Multimodality Monitoring. Intracranial pressure monitoring: fundamental considerations and rationale for monitoring. Neurocrit Care. 2014;21(Suppl 2):S64–84.PubMedCrossRef

39.

Chesnut RM, Temkin N, Carney N, Dikmen S, Rondina C, Videtta W, et al. A trial of intracranial-pressure monitoring in traumatic brain injury. N Engl J Med. 2012;367:2471–81.PubMedPubMedCentralCrossRef

40.

Farahvar A, Gerber LM, Chiu Y-L, Carney N, Härtl R, Ghajar J. Increased mortality in patients with severe traumatic brain injury treated without intracranial pressure monitoring. J Neurosurg. 2012;117:729–34.PubMedCrossRef

41.

Alali AS, Fowler RA, Mainprize TG, Scales DC, Kiss A, de Mestral C, et al. Intracranial pressure monitoring in severe traumatic brain injury: results from the American College of Surgeons Trauma Quality Improvement Program. J Neurotrauma. 2013;30:1737–46.PubMedPubMedCentralCrossRef

42.

Talving P, Karamanos E, Teixeira PG, Skiada D, Lam L, Belzberg H, et al. Intracranial pressure monitoring in severe head injury: compliance with Brain Trauma Foundation guidelines and effect on outcomes: a prospective study. J Neurosurg. 2013;119:1248–54.PubMedCrossRef

43.

Gerber LM, Chiu Y-L, Carney N, Härtl R, Ghajar J. Marked reduction in mortality in patients with severe traumatic brain injury. J Neurosurg. 2013;119:1583–90.PubMedCrossRef

44.

Horvat CM, Au AK, Conley YL, Kochanek PM, Li L, Poloyac SL, et al. ABCB1 genotype is associated with fentanyl requirements in critically ill children. Pediatr Res. 2017;82:29–35.PubMedPubMedCentralCrossRef

45.

Shein SL, Ferguson NM, Kochanek PM, Bayir H, Clark RSB, Fink EL, et al. Effectiveness of pharmacological therapies for intracranial hypertension in children with severe traumatic brain injury—results from an automated data collection system time-synched to drug administration. Pediatr Crit Care Med. 2016;17:236–45.PubMedPubMedCentralCrossRef

46.

Nwachuku EL, Puccio AM, Fetzick A, Scruggs B, Chang Y-F, Shutter LA, et al. Intermittent versus continuous cerebrospinal fluid drainage management in adult severe traumatic brain injury: assessment of intracranial pressure burden. Neurocrit Care. 2014;20:49–53.PubMedCrossRef

47.

Griesdale DEG, McEwen J, Kurth T, Chittock DR. External ventricular drains and mortality in patients with severe traumatic brain injury. Can J Neurol Sci. 2010;37:43–8.PubMedCrossRef

48.

Sakellaridis N, Pavlou E, Karatzas S, Chroni D, Vlachos K, Chatzopoulos K, et al. Comparison of mannitol and hypertonic saline in the treatment of severe brain injuries. J Neurosurg. 2011;114:545–8.PubMedCrossRef

49.

Mortazavi MM, Romeo AK, Deep A, Griessenauer CJ, Shoja MM, Tubbs RS, et al. Hypertonic saline for treating raised intracranial pressure: literature review with meta-analysis. J Neurosurg. 2012;116:210–21.PubMedCrossRef

50.

Gullans SR, Verbalis JG. Control of brain volume during hyperosmolar and hypoosmolar conditions. Annu Rev Med. 1993;44:289–301.PubMedCrossRef

51.

Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342:1581–9.PubMedCrossRef

52.

McManus ML, Churchwell KB, Strange K. Regulation of cell volume in health and disease. N Engl J Med. 1995;333:1260–6.PubMedCrossRef

53.

Doyle JA, Davis DP, Hoyt DB. The use of hypertonic saline in the treatment of traumatic brain injury. J Trauma. 2001;50:367–83.PubMedCrossRef

54.

Hauer E-M, Stark D, Staykov D, Steigleder T, Schwab S, Bardutzky J. Early continuous hypertonic saline infusion in patients with severe cerebrovascular disease. Crit Care Med. 2011;39:1766–72.PubMedCrossRef

55.

Wagner I, Hauer E-M, Staykov D, Volbers B, Dörfler A, Schwab S, et al. Effects of continuous hypertonic saline infusion on perihemorrhagic edema evolution. Stroke. 2011;42:1540–5.PubMedCrossRef

56.

Froelich M, Ni Q, Wess C, Ougorets I, Härtl R. Continuous hypertonic saline therapy and the occurrence of complications in neurocritically ill patients. Crit Care Med. 2009;37:1433–41.PubMedCrossRef

57.

Diringer MN. New trends in hyperosmolar therapy? Curr Opin Crit Care. 2013;19:77–82.PubMedPubMedCentralCrossRef

58.

Qiu W, Zhang Y, Sheng H, Zhang J, Wang W, Liu W, et al. Effects of therapeutic mild hypothermia on patients with severe traumatic brain injury after craniotomy. J Crit Care. 2007;22:229–35.PubMedCrossRef

59.

Jiang J-Y, Xu W, Li W-P, Gao G-Y, Bao Y-H, Liang Y-M, et al. Effect of long-term mild hypothermia or short-term mild hypothermia on outcome of patients with severe traumatic brain injury. J Cereb Blood Flow Metab. 2006;26:771–6.PubMedCrossRef

60.

Yan Y, Tang W, Deng Z, Zhong D, Yang G. Cerebral oxygen metabolism and neuroelectrophysiology in a clinical study of severe brain injury and mild hypothermia. J Clin Neurosci. 2010;17:196–200.PubMedCrossRef

61.

Jiang J, Yu M, Zhu C. Effect of long-term mild hypothermia therapy in patients with severe traumatic brain injury: 1-year follow-up review of 87 cases. J Neurosurg. 2000;93:546–9.PubMedCrossRef

62.

• Andrews PJD, Sinclair HL, Rodriguez A, Harris BA, Battison CG, Rhodes JKJ, et al. Hypothermia for intracranial hypertension after traumatic brain injury. N Engl J Med. 2015;373:2403–12 Recent landmark randomized controlled trial evaluating hypothermia for intracranial hypertension after TBI. PubMedCrossRef

63.

Jackson TC, Manole MD, Kotermanski SE, Jackson EK, Clark RSB, Kochanek PM. Cold stress protein RBM3 responds to temperature change in an ultra-sensitive manner in young neurons. Neuroscience. 2015;305:268–78.PubMedCrossRef

64.

Kochanek PM, Jackson TC. The brain and hypothermia—from Aristotle to targeted temperature management. Crit Care Med. 2017;45:305–10.PubMedPubMedCentralCrossRef

65.

Kochanek PM, Carney N, Adelson PD, Ashwal S, Bell MJ, Bratton S, et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents—second edition. Pediatr Crit Care Med. 2012;13(Suppl 1):S1–82.PubMed

66.

Zeiler FA, Donnelly J, Menon DK, Smielewski P, Hutchinson PJA, Czosnyka M. A description of a new continuous physiological index in traumatic brain injury using the correlation between pulse amplitude of intracranial pressure and cerebral perfusion pressure. J Neurotrauma. 2018.

67.

Aries MJH, Czosnyka M, Budohoski KP, Kolias AG, Radolovich DK, Lavinio A, et al. Continuous monitoring of cerebrovascular reactivity using pulse waveform of intracranial pressure. Neurocrit Care. 2012;17:67–76.PubMedCrossRef

68.

Sorrentino E, Diedler J, Kasprowicz M, Budohoski KP, Haubrich C, Smielewski P, et al. Critical thresholds for cerebrovascular reactivity after traumatic brain injury. Neurocrit. Care. 2012;16:258–66.PubMedCrossRef

69.

Zweifel C, Lavinio A, Steiner LA, Radolovich D, Smielewski P, Timofeev I, et al. Continuous monitoring of cerebrovascular pressure reactivity in patients with head injury. Neurosurg Focus. 2008;25:E2.PubMedCrossRef

70.

Czosnyka M, Smielewski P, Kirkpatrick P, Laing RJ, Menon D, Pickard JD. Continuous assessment of the cerebral vasomotor reactivity in head injury. Neurosurgery. 1997;41:11–7 discussion 17.PubMedCrossRef

71.

Czosnyka M, Smielewski P, Kirkpatrick P, Piechnik S, Laing R, Pickard JD. Continuous monitoring of cerebrovascular pressure-reactivity in head injury. Acta Neurochir Suppl. 1998;71:74–7.PubMed

72.

Steiner LA, Czosnyka M, Piechnik SK, Smielewski P, Chatfield D, Menon DK, et al. Continuous monitoring of cerebrovascular pressure reactivity allows determination of optimal cerebral perfusion pressure in patients with traumatic brain injury. Crit Care Med. 2002;30:733–8.PubMedCrossRef

73.

Howells T, Elf K, Jones PA, Ronne-Engström E, Piper I, Nilsson P, et al. Pressure reactivity as a guide in the treatment of cerebral perfusion pressure in patients with brain trauma. J Neurosurg. 2005;102:311–7.PubMedCrossRef

74.

Darby JM, Yonas H, Marion DW, Latchaw RE. Local “inverse steal” induced by hyperventilation in head injury. Neurosurgery. 1988;23:84–8.PubMedCrossRef

75.

Jha RM, Elmer J, Zusman BE, Desai S, Puccio AM, Okonkwo DO, et al. Intracranial pressure trajectories: a novel approach to informing severe traumatic brain injury phenotypes. Crit Care Med. 2018.

76.

Ito J, Marmarou A, Barzó P, Fatouros P, Corwin F. Characterization of edema by diffusion-weighted imaging in experimental traumatic brain injury. J Neurosurg. 1996;84:97–103.PubMedCrossRef

77.

Marmarou A. A review of progress in understanding the pathophysiology and treatment of brain edema. Neurosurg Focus. 2007;22:E1.PubMed

78.

Simard JM, Kent TA, Chen M, Tarasov KV, Gerzanich V. Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol. 2007;6:258–68.PubMedPubMedCentralCrossRef

79.

Stokum JA, Gerzanich V, Simard JM. Molecular pathophysiology of cerebral edema. J Cereb Blood Flow Metab. 2016;36:513–38.PubMedCrossRef

80.

Jha RM, Kochanek PM, Simard JM. Pathophysiology and treatment of cerebral edema in traumatic brain injury. Neuropharmacology. 2018.

81.

Iliff JJ, Chen MJ, Plog BA, Zeppenfeld DM, Soltero M, Yang L, et al. Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. J Neurosci. 2014;34:16180–93.PubMedPubMedCentralCrossRef

82.

Thrane AS, Rangroo Thrane V, Nedergaard M. Drowning stars: reassessing the role of astrocytes in brain edema. Trends Neurosci. 2014;37:620–8.PubMedPubMedCentralCrossRef

83.

Mackert BM, Staub F, Peters J, Baethmann A, Kempski O. Anoxia in vitro does not induce neuronal swelling or death. J Neurol Sci. 1996;139:39–47.PubMedCrossRef

84.

Kochanek PM, Clark RS, Ruppel RA, Dixon CE. Cerebral resuscitation after traumatic brain injury and cardiopulmonary arrest in infants and children in the new millennium. Pediatr Clin North Am. 2001;48:661–81.PubMedCrossRef

85.

Barzó P, Marmarou A, Fatouros P, Hayasaki K, Corwin F. Contribution of vasogenic and cellular edema to traumatic brain swelling measured by diffusion-weighted imaging. J Neurosurg. 1997;87:900–7.PubMedCrossRef

86.

Marmarou A, Signoretti S, Fatouros PP, Portella G, Aygok GA, Bullock MR. Predominance of cellular edema in traumatic brain swelling in patients with severe head injuries. J Neurosurg. 2006;104:720–30.PubMedCrossRef

87.

Whalen MJ, Carlos TM, Wisniewski SR, Clark RS, Mellick JA, Marion DW, et al. Effect of neutropenia and granulocyte colony stimulating factor-induced neutrophilia on blood-brain barrier permeability and brain edema after traumatic brain injury in rats. Crit Care Med. 2000;28:3710–7.PubMedCrossRef

88.

Tanno H, Nockels RP, Pitts LH, Noble LJ. Breakdown of the blood-brain barrier after fluid percussive brain injury in the rat. Part 1: distribution and time course of protein extravasation. J. Neurotrauma. 1992;9:21–32.CrossRef

89.

Readnower RD, Chavko M, Adeeb S, Conroy MD, Pauly JR, McCarron RM, et al. Increase in blood-brain barrier permeability, oxidative stress, and activated microglia in a rat model of blast-induced traumatic brain injury. J Neurosci Res. 2010;88:3530–9.PubMedPubMedCentralCrossRef

90.

Shetty AK, Mishra V, Kodali M, Hattiangady B. Blood brain barrier dysfunction and delayed neurological deficits in mild traumatic brain injury induced by blast shock waves. Front Cell Neurosci. 2014;8:232.PubMedPubMedCentral

91.

Yeoh S, Bell ED, Monson KL. Distribution of blood-brain barrier disruption in primary blast injury. Ann Biomed Eng. 2013;41:2206–14.PubMedCrossRef

92.

Papadopoulos MC, Verkman AS. Aquaporin water channels in the nervous system. Nat Rev Neurosci. 2013;14:265–77.PubMedPubMedCentralCrossRef

93.

Stokum JA, Kwon MS, Woo SK, Tsymbalyuk O, Vennekens R, Gerzanich V, et al. SUR1-TRPM4 and AQP4 form a heteromultimeric complex that amplifies ion/water osmotic coupling and drives astrocyte swelling. Glia. 2018;66:108–25.PubMedCrossRef

94.

Laird MD, Shields JS, Sukumari-Ramesh S, Kimbler DE, Fessler RD, Shakir B, et al. High mobility group box protein-1 promotes cerebral edema after traumatic brain injury via activation of toll-like receptor 4. Glia. 2014;62:26–38.PubMedCrossRef

95.

Filippidis AS, Carozza RB, Rekate HL. Aquaporins in brain edema and neuropathological conditions. Int J Mol Sci. 2016;18.PubMedCentralCrossRef

96.

Hubbard JA, Szu JI, Binder DK. The role of aquaporin-4 in synaptic plasticity, memory and disease. Brain Res Bull. 2018;136:118–29.PubMedCrossRef

97.

Cartagena CM, Phillips KL, Tortella FC, Dave JR, Schmid KE. Temporal alterations in aquaporin and transcription factor HIF1α expression following penetrating ballistic-like brain injury (PBBI). Mol Cell Neurosci. 2014;60:81–7.PubMedCrossRef

98.

Ke C, Poon WS, Ng HK, Pang JC, Chan Y. Heterogeneous responses of aquaporin-4 in oedema formation in a replicated severe traumatic brain injury model in rats. Neurosci Lett. 2001;301:21–4.PubMedCrossRef

99.

Kiening KL, van Landeghem FKH, Schreiber S, Thomale UW, von Deimling A, Unterberg AW, et al. Decreased hemispheric Aquaporin-4 is linked to evolving brain edema following controlled cortical impact injury in rats. Neurosci Lett. 2002;324:105–8.CrossRefPubMed

100.

Liu H, Qiu G p, Zhuo F, Yu W h, Sun S q, Li F h, et al. Lost polarization of aquaporin4 and dystroglycan in the core lesion after traumatic brain injury suggests functional divergence in evolution. Biomed Res Int. 2015;2015:471631.PubMedPubMedCentral

101.

Zhang C, Chen J, Lu H. Expression of aquaporin-4 and pathological characteristics of brain injury in a rat model of traumatic brain injury. Mol Med Rep. 2015;12:7351–7.PubMedPubMedCentralCrossRef

102.

Taya K, Marmarou CR, Okuno K, Prieto R, Marmarou A. Effect of secondary insults upon aquaporin-4 water channels following experimental cortical contusion in rats. J Neurotrauma. 2010;27:229–39.PubMedPubMedCentralCrossRef

103.

Lopez-Rodriguez AB, Acaz-Fonseca E, Viveros M-P, Garcia-Segura LM. Changes in cannabinoid receptors, aquaporin 4 and vimentin expression after traumatic brain injury in adolescent male mice. Association with edema and neurological deficit. PLoS One. 2015;10:e0128782.PubMedPubMedCentralCrossRef

104.

Lu H, Lei X-Y, Hu H, He Z-P. Relationship between AQP4 expression and structural damage to the blood-brain barrier at early stages of traumatic brain injury in rats. Chin Med J. 2013;126:4316–21.PubMed

105.

Ren Z, Iliff JJ, Yang L, Yang J, Chen X, Chen MJ, et al. “Hit & Run” model of closed-skull traumatic brain injury (TBI) reveals complex patterns of post-traumatic AQP4 dysregulation. J Cereb Blood Flow Metab. 2013;33:834–45.PubMedPubMedCentralCrossRef

106.

Yao X, Uchida K, Papadopoulos MC, Zador Z, Manley GT, Verkman AS. Mildly reduced brain swelling and improved neurological outcome in aquaporin-4 knockout mice following controlled cortical impact brain injury. J Neurotrauma. 2015;32:1458–64.PubMedPubMedCentralCrossRef

107.

Hu H, Yao H, Zhang W, Zhang L, Ding W, Zhang S, et al. Increased expression of aquaporin-4 in human traumatic brain injury and brain tumors. J Zhejiang Univ Sci B. 2005;6:33–7.PubMedCrossRef

108.

Lo Pizzo M, Schiera G, Di Liegro I, Di Liegro CM, Pál J, Czeiter E, et al. Aquaporin-4 distribution in control and stressed astrocytes in culture and in the cerebrospinal fluid of patients with traumatic brain injuries. Neurol Sci. 2013;34:1309–14.PubMedCrossRef

109.

Dardiotis E, Paterakis K, Tsivgoulis G, Tsintou M, Hadjigeorgiou GF, Dardioti M, et al. AQP4 tag single nucleotide polymorphisms in patients with traumatic brain injury. J Neurotrauma. 2014;31:1920–6.PubMedPubMedCentralCrossRef

110.

Chen J-Q, Zhang C-C, Jiang S-N, Lu H, Wang W. Effects of aquaporin 4 knockdown on brain edema of the uninjured side after traumatic brain injury in rats. Med Sci Monit. 2016;22:4809–19.PubMedPubMedCentralCrossRef

111.

Fukuda AM, Adami A, Pop V, Bellone JA, Coats JS, Hartman RE, et al. Posttraumatic reduction of edema with aquaporin-4 RNA interference improves acute and chronic functional recovery. J Cereb Blood Flow Metab. 2013;33:1621–32.PubMedPubMedCentralCrossRef

112.

Higashida T, Kreipke CW, Rafols JA, Peng C, Schafer S, Schafer P, et al. The role of hypoxia-inducible factor-1α, aquaporin-4, and matrix metalloproteinase-9 in blood-brain barrier disruption and brain edema after traumatic brain injury. J Neurosurg. 2011;114:92–101.PubMedCrossRef

113.

Manley GT, Fujimura M, Ma T, Noshita N, Filiz F, Bollen AW, et al. Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med. 2000;6:159–63.CrossRefPubMed

114.

Papadopoulos MC, Manley GT, Krishna S, Verkman AS. Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J. 2004;18:1291–3.PubMedCrossRef

115.

Zhang M, Cui Z, Cui H, Cao Y, Zhong C, Wang Y. Astaxanthin alleviates cerebral edema by modulating NKCC1 and AQP4 expression after traumatic brain injury in mice. BMC Neurosci. 2016;17:60.PubMedPubMedCentralCrossRef

116.

Ding Z, Zhang J, Xu J, Sheng G, Huang G. Propofol administration modulates AQP-4 expression and brain edema after traumatic brain injury. Cell Biochem Biophys. 2013;67:615–22.PubMedCrossRef

117.

Wang X, Zhang J, Yang Y, Dong W, Wang F, Wang L, et al. Progesterone attenuates cerebral edema in neonatal rats with hypoxic-ischemic brain damage by inhibiting the expression of matrix metalloproteinase-9 and aquaporin-4. Exp Ther Med. 2013;6:263–7.PubMedPubMedCentralCrossRef

118.

Wallisch J, Jha R, Vagni V, Feldman K, Dixon C, Farr G, et al. Effect of the novel aquaporin-4 antagonist AER-271 in combined TBI plus hemorrhagic shock in mice. Crit Care Med. 2015;43:6–7.CrossRef

119.

Lopez NE, Krzyzaniak MJ, Blow C, Putnam J, Ortiz-Pomales Y, Hageny A-M, et al. Ghrelin prevents disruption of the blood-brain barrier after traumatic brain injury. J Neurotrauma. 2012;29:385–93.PubMedPubMedCentralCrossRef

120.

Ballarin B, Tymianski M. Discovery and development of NA-1 for the treatment of acute ischemic stroke. Acta Pharmacol Sin. 2018;39:661–8.PubMedPubMedCentralCrossRef

121.

Pál B. Involvement of extrasynaptic glutamate in physiological and pathophysiological changes of neuronal excitability. Cell Mol Life Sci. 2018;

122.

Kostic M, Zivkovic N, Stojanovic I. Multiple sclerosis and glutamate excitotoxicity. Rev Neurosci. 2013;24:71–88.PubMedCrossRef

123.

Plitman E, Nakajima S, de la Fuente-Sandoval C, Gerretsen P, Chakravarty MM, Kobylianskii J, et al. Glutamate-mediated excitotoxicity in schizophrenia: a review. Eur. Neuropsychopharmacol. 2014;24:1591–605.PubMedPubMedCentralCrossRef

124.

Chodobski A, Zink BJ, Szmydynger-Chodobska J. Blood-brain barrier pathophysiology in traumatic brain injury. Transl Stroke Res. 2011;2:492–516.PubMedPubMedCentralCrossRef

125.

Nilsson P, Hillered L, Pontén U, Ungerstedt U. Changes in cortical extracellular levels of energy-related metabolites and amino acids following concussive brain injury in rats. J Cereb Blood Flow Metab. 1990;10:631–7.PubMedCrossRef

126.

Hillered L, Persson L, Carlson H, Ungerstedt U, Ronne-Engström E, Nilsson P. Studies on excitatory amino acid receptor-linked brain disorders in rat and man using in vivo microdialysis. Clin Neuropharmacol. 1992;15(Suppl 1 Pt A):695A–6A.PubMedCrossRef

127.

Chamoun R, Suki D, Gopinath SP, Goodman JC, Robertson C. Role of extracellular glutamate measured by cerebral microdialysis in severe traumatic brain injury. J. Neurosurg. 2010;113:564–70.PubMedPubMedCentralCrossRef

128.

Koura SS, Doppenberg EM, Marmarou A, Choi S, Young HF, Bullock R. Relationship between excitatory amino acid release and outcome after severe human head injury. Acta Neurochir Suppl. 1998;71:244–6.PubMed

129.

Bullock R, Zauner A, Woodward JJ, Myseros J, Choi SC, Ward JD, et al. Factors affecting excitatory amino acid release following severe human head injury. J Neurosurg. 1998;89:507–18.PubMedCrossRef

130.

Stefani MA, Modkovski R, Hansel G, Zimmer ER, Kopczynski A, Muller AP, et al. Elevated glutamate and lactate predict brain death after severe head trauma. Ann Clin Transl Neurol. 2017;4:392–402.PubMedPubMedCentralCrossRef

131.

Zauner A, Bullock R, Kuta AJ, Woodward J, Young HF. Glutamate release and cerebral blood flow after severe human head injury. Acta Neurochir Suppl. 1996;67:40–4.PubMed

132.

Sönmez A, Sayın O, Gürgen SG, Çalişir M. Neuroprotective effects of MK-801 against traumatic brain injury in immature rats. Neurosci Lett. 2015;597:137–42.PubMedCrossRef

133.

Imer M, Omay B, Uzunkol A, Erdem T, Sabanci PA, Karasu A, et al. Effect of magnesium, MK-801 and combination of magnesium and MK-801 on blood-brain barrier permeability and brain edema after experimental traumatic diffuse brain injury. Neurol Res. 2009;31:977–81.PubMedCrossRef

134.

Görgülü A, Kiriş T, Unal F, Türkoğlu U, Küçük M, Cobanoğlu S. Protective effect of the N-methyl-D-aspartate receptor antagonists, MK-801 and CPP on cold-induced brain oedema. Acta Neurochir (Wien). 1999;141:93–8.CrossRef

135.

Day NL, Carle MS, Floyd CL. Post-injury administration of a combination of memantine and 17β-estradiol is protective in a rat model of traumatic brain injury. Neurochem Int. 2017;111:57–68.PubMedCrossRef

136.

Muir KW. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol. 2006;6:53–60.PubMedCrossRef

137.

Willis C, Lybrand S, Bellamy N. Excitatory amino acid inhibitors for traumatic brain injury. Cochrane Database Syst Rev. 2004;CD003986.

138.

Gultekin R, Huang S, Clavisi O, Pattuwage L, König TC, Gruen R. Pharmacological interventions in traumatic brain injury: can we rely on systematic reviews for evidence? Injury. 2016;47:516–24.PubMedCrossRef

139.

Vespa PM, Miller C, McArthur D, Eliseo M, Etchepare M, Hirt D, et al. Nonconvulsive electrographic seizures after traumatic brain injury result in a delayed, prolonged increase in intracranial pressure and metabolic crisis. Crit Care Med. 2007;35:2830–6.PubMedPubMedCentralCrossRef

140.

Simon DW, McGeachy MJ, Bayır H, Clark RSB, Loane DJ, Kochanek PM. The far-reaching scope of neuroinflammation after traumatic brain injury. Nat Rev Neurol. 2017;13:171–91.PubMedPubMedCentralCrossRef

141.

Jassam YN, Izzy S, Whalen M, McGavern DB, El Khoury J. Neuroimmunology of traumatic brain injury: time for a paradigm shift. Neuron. 2017;95:1246–65.PubMedPubMedCentralCrossRef

142.

Corrigan F, Mander KA, Leonard AV, Vink R. Neurogenic inflammation after traumatic brain injury and its potentiation of classical inflammation. J Neuroinflammation. 2016;13:264.PubMedPubMedCentralCrossRef

143.

Alluri H, Wilson RL, Anasooya Shaji C, Wiggins-Dohlvik K, Patel S, Liu Y, et al. Melatonin preserves blood-brain barrier integrity and permeability via matrix metalloproteinase-9 inhibition. PLoS One. 2016;11:e0154427.PubMedPubMedCentralCrossRef

144.

Guilfoyle MR, Carpenter KLH, Helmy A, Pickard JD, Menon DK, Hutchinson PJA. Matrix metalloproteinase expression in contusional traumatic brain injury: a paired microdialysis study. J Neurotrauma. 2015;32:1553–9.PubMedPubMedCentralCrossRef

145.

Hadass O, Tomlinson BN, Gooyit M, Chen S, Purdy JJ, Walker JM, et al. Selective inhibition of matrix metalloproteinase-9 attenuates secondary damage resulting from severe traumatic brain injury. PLoS One. 2013;8:e76904.PubMedPubMedCentralCrossRef

146.

Rosenberg GA, Yang Y. Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurg Focus. 2007;22:E4.PubMedCrossRef

147.

Bolton SJ, Anthony DC, Perry VH. Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood-brain barrier breakdown in vivo. Neuroscience. 1998;86:1245–57.PubMedCrossRef

148.

Walker K, Perkins M, Dray A. Kinins and kinin receptors in the nervous system. Neurochem Int. 1995;26:1–16 discussion 17.PubMedCrossRef

149.

Mankertz J, Tavalali S, Schmitz H, Mankertz A, Riecken EO, Fromm M, et al. Expression from the human occludin promoter is affected by tumor necrosis factor alpha and interferon gamma. J Cell Sci. 2000;113(Pt 11):2085–90.PubMedCrossRef

150.

Wójciak-Stothard B, Entwistle A, Garg R, Ridley AJ. Regulation of TNF-alpha-induced reorganization of the actin cytoskeleton and cell-cell junctions by Rho, Rac, and Cdc42 in human endothelial cells. J Cell Physiol. 1998;176:150–65.PubMedCrossRef

151.

Morganti-Kossmann MC, Hans VH, Lenzlinger PM, Dubs R, Ludwig E, Trentz O, et al. TGF-beta is elevated in the CSF of patients with severe traumatic brain injuries and parallels blood-brain barrier function. J Neurotrauma. 1999;16:617–28.PubMedCrossRef

152.

Buttram SDW, Wisniewski SR, Jackson EK, Adelson PD, Feldman K, Bayir H, et al. Multiplex assessment of cytokine and chemokine levels in cerebrospinal fluid following severe pediatric traumatic brain injury: effects of moderate hypothermia. J Neurotrauma. 2007;24:1707–17.PubMedCrossRef

153.

Helmy A, Carpenter KLH, Menon DK, Pickard JD, Hutchinson PJA. The cytokine response to human traumatic brain injury: temporal profiles and evidence for cerebral parenchymal production. J Cereb Blood Flow Metab. 2011;31:658–70.PubMedCrossRef

154.

Maier B, Schwerdtfeger K, Mautes A, Holanda M, Müller M, Steudel WI, et al. Differential release of interleukines 6, 8, and 10 in cerebrospinal fluid and plasma after traumatic brain injury. Shock. 2001;15:421–6.PubMedCrossRef

155.

Whalen MJ, Carlos TM, Kochanek PM, Wisniewski SR, Bell MJ, Clark RS, et al. Interleukin-8 is increased in cerebrospinal fluid of children with severe head injury. Crit Care Med. 2000;28:929–34.PubMedCrossRef

156.

Stamatovic SM, Keep RF, Kunkel SL, Andjelkovic AV. Potential role of MCP-1 in endothelial cell tight junction “opening”: signaling via Rho and Rho kinase. J Cell Sci. 2003;116:4615–28.CrossRefPubMed

157.

Woodcock TM, Frugier T, Nguyen TT, Semple BD, Bye N, Massara M, et al. The scavenging chemokine receptor ACKR2 has a significant impact on acute mortality rate and early lesion development after traumatic brain injury. PLoS One. 2017;12:e0188305.PubMedPubMedCentralCrossRef

158.

da Fonseca ACC, Matias D, Garcia C, Amaral R, Geraldo LH, Freitas C, et al. The impact of microglial activation on blood-brain barrier in brain diseases. Front Cell Neurosci. 2014;8:362.PubMedPubMedCentralCrossRef

159.

Shen W, Li S, Chung SH, Zhu L, Stayt J, Su T, et al. Tyrosine phosphorylation of VE-cadherin and claudin-5 is associated with TGF-β1-induced permeability of centrally derived vascular endothelium. Eur J Cell Biol. 2011;90:323–32.PubMedCrossRef

160.

Stahel PF, Morganti-Kossmann MC, Perez D, Redaelli C, Gloor B, Trentz O, et al. Intrathecal levels of complement-derived soluble membrane attack complex (sC5b-9) correlate with blood-brain barrier dysfunction in patients with traumatic brain injury. J Neurotrauma. 2001;18:773–81.PubMedCrossRef

161.

Kossmann T, Stahel PF, Morganti-Kossmann MC, Jones JL, Barnum SR. Elevated levels of the complement components C3 and factor B in ventricular cerebrospinal fluid of patients with traumatic brain injury. J Neuroimmunol. 1997;73:63–9.PubMedCrossRef

162.

Kumar RG, Rubin JE, Berger RP, Kochanek PM, Wagner AK. Principal components derived from CSF inflammatory profiles predict outcome in survivors after severe traumatic brain injury. Brain Behav Immun. 2016;53:183–93.PubMedCrossRef

163.

Edwards P, Arango M, Balica L, Cottingham R, El-Sayed H, Farrell B, et al. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet. 2005;365:1957–9.PubMedCrossRef

164.

Roberts I, Yates D, Sandercock P, Farrell B, Wasserberg J, Lomas G, et al. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet. 2004;364:1321–8.PubMedCrossRef

165.

Thal SC, Heinemann M, Luh C, Pieter D, Werner C, Engelhard K. Pioglitazone reduces secondary brain damage after experimental brain trauma by PPAR-γ-independent mechanisms. J Neurotrauma. 2011;28:983–93.PubMedCrossRef

166.

Chen XR, Besson VC, Palmier B, Garcia Y, Plotkine M, Marchand-Leroux C. Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury. J Neurotrauma. 2007;24:1119–31.PubMedCrossRef

167.

Besson VC, Chen XR, Plotkine M, Marchand-Verrecchia C. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, exerts neuroprotective effects in traumatic brain injury. Neurosci Lett. 2005;388:7–12.PubMedCrossRef

168.

Thal SC, Neuhaus W. The blood-brain barrier as a target in traumatic brain injury treatment. Arch Med Res. 2014;45:698–710.PubMedCrossRef

169.

Yi J-H, Park S-W, Brooks N, Lang BT, Vemuganti R. PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res. 2008;1244:164–72.PubMedPubMedCentralCrossRef

170.

Sauerbeck A, Gao J, Readnower R, Liu M, Pauly JR, Bing G, et al. Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury. Exp Neurol. 2011;227:128–35.PubMedCrossRef

171.

Gonzales NR, Shah J, Sangha N, Sosa L, Martinez R, Shen L, et al. Design of a prospective, dose-escalation study evaluating the safety of pioglitazone for hematoma resolution in intracerebral hemorrhage (SHRINC). Int J Stroke. 2013;8:388–96.PubMedCrossRef

172.

Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321–31.PubMedPubMedCentralCrossRef

173.

Mandrekar-Colucci S, Sauerbeck A, Popovich PG, McTigue DM. PPAR agonists as therapeutics for CNS trauma and neurological diseases. ASN Neuro. 2013;5:e00129.PubMedPubMedCentralCrossRef

174.

Negrotto L, Farez MF, Correale J. Immunologic effects of metformin and pioglitazone treatment on metabolic syndrome and multiple sclerosis. JAMA Neurol. 2016;73:520–8.PubMedCrossRef

175.

Hau P, Kunz-Schughart L, Bogdahn U, Baumgart U, Hirschmann B, Weimann E, et al. Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas—a phase II study. Oncology. 2007;73:21–5.PubMedCrossRef

176.

Au AK, Aneja RK, Bell MJ, Bayir H, Feldman K, Adelson PD, et al. Cerebrospinal fluid levels of high-mobility group box 1 and cytochrome C predict outcome after pediatric traumatic brain injury. J Neurotrauma. 2012;29:2013–21.PubMedPubMedCentralCrossRef

177.

Lu L, Wang M, Yuan F, Wei X, Li W. Roles of elevated 20-HETE in the breakdown of blood brain barrier and the severity of brain edema in experimental traumatic brain injury. Mol Med Rep. 2018;17:7339–45.PubMed

178.

Zhang J, Pu H, Zhang H, Wei Z, Jiang X, Xu M, et al. Inhibition of Na+-K+-2Cl-cotransporter attenuates blood-brain-barrier disruption in a mouse model of traumatic brain injury. Neurochem Int. 2017;111:23–31.PubMedCrossRef

179.

Roberts DJ, Jenne CN, Léger C, Kramer AH, Gallagher CN, Todd S, et al. A prospective evaluation of the temporal matrix metalloproteinase response after severe traumatic brain injury in humans. J Neurotrauma. 2013;30:1717–26.PubMedCrossRef

180.

Kimberly WT, Battey TWK, Pham L, Wu O, Yoo AJ, Furie KL, et al. Glyburide is associated with attenuated vasogenic edema in stroke patients. Neurocrit Care. 2014;20:193–201.PubMedPubMedCentralCrossRef

181.

Serena J, Blanco M, Castellanos M, Silva Y, Vivancos J, Moro MA, et al. The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke. 2005;36:1921–6.PubMedCrossRef

182.

Jha R, Battey TWK, Pham L, Lorenzano S, Furie KL, Sheth KN, et al. Fluid-attenuated inversion recovery hyperintensity correlates with matrix metalloproteinase-9 level and hemorrhagic transformation in acute ischemic stroke. Stroke. 2014;45:1040–5.PubMedPubMedCentralCrossRef

183.

Simard JM, Geng Z, Silver FL, Sheth KN, Kimberly WT, Stern BJ, et al. Does inhibiting Sur1 complement rt-PA in cerebral ischemia? Ann N Y Acad Sci. 2012;1268:95–107.PubMedPubMedCentralCrossRef

184.

Sheth KN, Elm JJ, Molyneaux BJ, Hinson H, Beslow LA, Sze GK, et al. Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2016;15:1160–9.PubMedCrossRef

185.

Muradashvili N, Benton RL, Saatman KE, Tyagi SC, Lominadze D. Ablation of matrix metalloproteinase-9 gene decreases cerebrovascular permeability and fibrinogen deposition post traumatic brain injury in mice. Metab Brain Dis. 2015;30:411–26.PubMedCrossRef

186.

Semple BD, Noble-Haeusslein LJ, Gooyit M, Tercovich KG, Peng Z, Nguyen TT, et al. Early gelatinase activity is not a determinant of long-term recovery after traumatic brain injury in the immature mouse. PLoS One. 2015;10:e0143386.PubMedPubMedCentralCrossRef

187.

Wang X, Jung J, Asahi M, Chwang W, Russo L, Moskowitz MA, et al. Effects of matrix metalloproteinase-9 gene knock-out on morphological and motor outcomes after traumatic brain injury. J Neurosci. 2000;20:7037–42.PubMedCrossRefPubMedCentral

188.

Liu J, Jin X, Liu KJ, Liu W. Matrix metalloproteinase-2-mediated occludin degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood-brain barrier damage in early ischemic stroke stage. J Neurosci. 2012;32:3044–57.PubMedPubMedCentralCrossRef

189.

Cui J, Chen S, Zhang C, Meng F, Wu W, Hu R, et al. Inhibition of MMP-9 by a selective gelatinase inhibitor protects neurovasculature from embolic focal cerebral ischemia. Mol Neurodegener. 2012;7:21.PubMedPubMedCentralCrossRef

190.

Jia F, Yin YH, Gao GY, Wang Y, Cen L, Jiang J-Y. MMP-9 inhibitor SB-3CT attenuates behavioral impairments and hippocampal loss after traumatic brain injury in rat. J Neurotrauma. 2014;31:1225–34.PubMedPubMedCentralCrossRef

191.

Zhao B-Q, Wang S, Kim H-Y, Storrie H, Rosen BR, Mooney DJ, et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med. 2006;12:441–5.PubMedCrossRef

192.

Jayakumar AR, Panickar KS, Curtis KM, Tong XY, Moriyama M, Norenberg MD. Na-K-Cl cotransporter-1 in the mechanism of cell swelling in cultured astrocytes after fluid percussion injury. J Neurochem. 2011;117:437–48.PubMedCrossRef

193.

Lu K-T, Huang T-C, Tsai Y-H, Yang Y-L. Transient receptor potential vanilloid type 4 channels mediate Na-K-Cl-co-transporter-induced brain edema after traumatic brain injury. J Neurochem. 2017;140:718–27.PubMedCrossRef

194.

Simard JM, Kahle KT, Gerzanich V. Molecular mechanisms of microvascular failure in central nervous system injury—synergistic roles of NKCC1 and SUR1/TRPM4. J Neurosurg. 2010;113:622–9.PubMedPubMedCentralCrossRef

195.

Lu K-T, Cheng N-C, Wu C-Y, Yang Y-L. NKCC1-mediated traumatic brain injury-induced brain edema and neuron death via Raf/MEK/MAPK cascade. Crit Care Med. 2008;36:917–22.PubMedCrossRef

196.

Lu K-T, Wu C-Y, Cheng N-C, Wo Y-YP, Yang J-T, Yen H-H, et al. Inhibition of the Na+ -K+ -2Cl- -cotransporter in choroid plexus attenuates traumatic brain injury-induced brain edema and neuronal damage. Eur J Pharmacol. 2006;548:99–105.PubMedCrossRef

197.

Jayakumar AR, Taherian M, Panickar KS, Shamaladevi N, Rodriguez ME, Price BG, et al. Differential response of neural cells to trauma-induced swelling in vitro. Neurochem Res. 2018;43:397–406.PubMedCrossRef

198.

Simard JM, Kilbourne M, Tsymbalyuk O, Tosun C, Caridi J, Ivanova S, et al. Key role of sulfonylurea receptor 1 in progressive secondary hemorrhage after brain contusion. J Neurotrauma. 2009;26:2257–67.PubMedPubMedCentralCrossRef

199.

Simard JM, Woo SK, Schwartzbauer GT, Gerzanich V. Sulfonylurea receptor 1 in central nervous system injury: a focused review. J Cereb Blood Flow Metab. 2012;32:1699–717.PubMedPubMedCentralCrossRef

200.

Jha RM, Puccio AM, Okonkwo DO, Zusman BE, Park S-Y, Wallisch J, et al. ABCC8 single nucleotide polymorphisms are associated with cerebral edema in severe TBI. Neurocrit Care. 2017;26:213–24.PubMedPubMedCentralCrossRef

201.

Jha RM, Elmer J, Zusman B, Puccio A, Okonkwo D, Shutter L, et al. Intracranial pressure trajectories: a novel tool to inform severe TBI phenotypes. Crit Care Med. 2018;46:16.CrossRef

202.

Jha R, Puccio A, Okonkwo D, Zusman B, Koleck T, Wallisch J, et al. 785 TRPM-4 single nucleotide polymorphisms correlate with cerebral edema in traumatic brain injury. Crit Care Med. 2018;46:378.CrossRef

203.

Jha RM, Molyneaux BJ, Jackson TC, Wallisch JS, Park S-Y, Poloyac S, et al. Glibenclamide produces region-dependent effects on cerebral edema in a combined injury model of traumatic brain injury and hemorrhagic shock in mice. J Neurotrauma. 2018.

204.

Zweckberger K, Hackenberg K, Jung CS, Hertle DN, Kiening KL, Unterberg AW, et al. Glibenclamide reduces secondary brain damage after experimental traumatic brain injury. Neuroscience. 2014;272:199–206.PubMedCrossRef

205.

Patel AD, Gerzanich V, Geng Z, Simard JM. Glibenclamide reduces hippocampal injury and preserves rapid spatial learning in a model of traumatic brain injury. J Neuropathol Exp Neurol. 2010;69:1177–90.PubMedCrossRef

206.

Jha R, Yan H, Dixon CE, Poloyac S, Jackson T, Hoshitsuki K, et al. Evaluation of glibenclamide in the pittsburgh controlled cortical impact model of traumatic brain injury: an OBTT Consortium Study. J Neurotrauma. 2015;32:119.

207.

Khalili H, Derakhshan N, Niakan A, Ghaffarpasand F, Salehi M, Eshraghian H, et al. Effects of oral glibenclamide on brain contusion volume and functional outcome of patients with moderate and severe traumatic brain injuries: a randomized double-blind placebo-controlled clinical trial. World Neurosurg. 2017;101:130–6.PubMedCrossRef

208.

Zafardoost P, Ghasemi AA, Salehpour F, Piroti C, Ziaeii E. Evaluation of the effect of glibenclamide in patients with diffuse axonal injury due to moderate to severe head trauma. Trauma Mon. 2016;21:e25113.PubMedPubMedCentralCrossRef

209.

Suzuki R, Fukai N, Nagashijma G, Asai JI, Itokawa H, Nagai M, et al. Very early expression of vascular endothelial growth factor in brain oedema tissue associated with brain contusion. Acta Neurochir Suppl. 2003;86:277–9.PubMed

210.

Chodobski A, Chung I, Koźniewska E, Ivanenko T, Chang W, Harrington JF, et al. Early neutrophilic expression of vascular endothelial growth factor after traumatic brain injury. Neuroscience. 2003;122:853–67.PubMedCrossRef

211.

Argaw AT, Gurfein BT, Zhang Y, Zameer A, John GR. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc Natl Acad Sci U S A. 2009;106:1977–82.PubMedPubMedCentralCrossRef

212.

Murakami T, Felinski EA, Antonetti DA. Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability. J Biol Chem. 2009;284:21036–46.PubMedPubMedCentralCrossRef

213.

Wang W, Dentler WL, Borchardt RT. VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly. Am J Physiol Heart Circ Physiol. 2001;280:H434–40.PubMedCrossRef

214.

Salehi A, Zhang JH, Obenaus A. Response of the cerebral vasculature following traumatic brain injury. J Cereb Blood Flow Metab. 2017;37:2320–39.PubMedPubMedCentralCrossRef

215.

Thau-Zuchman O, Shohami E, Alexandrovich AG, Leker RR. Vascular endothelial growth factor increases neurogenesis after traumatic brain injury. J Cereb Blood Flow Metab. 2010;30:1008–16.PubMedPubMedCentralCrossRef

216.

Clausen F, Marklund N, Hillered L. Acute inflammatory biomarker responses to diffuse traumatic brain injury in the rat monitored by a novel microdialysis technique. J Neurotrauma. 2018.

217.

Shore PM, Jackson EK, Wisniewski SR, Clark RSB, Adelson PD, Kochanek PM. Vascular endothelial growth factor is increased in cerebrospinal fluid after traumatic brain injury in infants and children. Neurosurgery. 2004;54:605–11 discussion 611.PubMedCrossRef

218.

Li M, Jia Q, Chen T, Zhao Z, Chen J, Zhang J. The role of vascular endothelial growth factor and vascular endothelial growth inhibitor in clinical outcome of traumatic brain injury. Clin Neurol Neurosurg. 2016;144:7–13.PubMedCrossRef

219.

Gao W, Zhao Z, Yu G, Zhou Z, Zhou Y, Hu T, et al. VEGI attenuates the inflammatory injury and disruption of blood-brain barrier partly by suppressing the TLR4/NF-κB signaling pathway in experimental traumatic brain injury. Brain Res. 2015;1622:230–9.PubMedCrossRef

220.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N. Antiangiogenic therapy for high-grade glioma. Cochrane Database Syst Rev. 2014;CD008218.

221.

Tado M, Mori T, Fukushima M, Oshima H, Maeda T, Yoshino A, et al. Increased expression of vascular endothelial growth factor attenuates contusion necrosis without influencing contusion edema after traumatic brain injury in rats. J Neurotrauma. 2014;31:691–8.PubMedCrossRef

222.

Badri S, Chen J, Barber J, Temkin NR, Dikmen SS, Chesnut RM, et al. Mortality and long-term functional outcome associated with intracranial pressure after traumatic brain injury. Intensive Care Med. 2012;38:1800–9.PubMedCrossRef

223.

Balestreri M, Czosnyka M, Hutchinson P, Steiner LA, Hiler M, Smielewski P, et al. Impact of intracranial pressure and cerebral perfusion pressure on severe disability and mortality after head injury. Neurocrit Care. 2006;4:8–13.PubMedCrossRef

224.

Lannoo E, Van Rietvelde F, Colardyn F, Lemmerling M, Vandekerckhove T, Jannes C, et al. Early predictors of mortality and morbidity after severe closed head injury. J Neurotrauma. 2000;17:403–14.PubMedCrossRef

225.

Czosnyka M, Hutchinson PJ, Balestreri M, Hiler M, Smielewski P, Pickard JD. Monitoring and interpretation of intracranial pressure after head injury. Acta Neurochir Suppl. 2006;96:114–8.PubMedCrossRef

226.

Struchen MA, Hannay HJ, Contant CF, Robertson CS. The relation between acute physiological variables and outcome on the Glasgow Outcome Scale and Disability Rating Scale following severe traumatic brain injury. J Neurotrauma. 2001;18:115–25.PubMedCrossRef

227.

Levin HS, Eisenberg HM, Gary HE, Marmarou A, Foulkes MA, Jane JA, et al. Intracranial hypertension in relation to memory functioning during the first year after severe head injury. Neurosurgery. 1991;28:196–9 discussion 200.PubMedCrossRef

228.

Yue JK, Vassar MJ, Lingsma HF, Cooper SR, Okonkwo DO, Valadka AB, et al. Transforming research and clinical knowledge in traumatic brain injury pilot: multicenter implementation of the common data elements for traumatic brain injury. J Neurotrauma. 2013;30:1831–44.PubMedPubMedCentralCrossRef

229.

Kochanek PM, Bramlett HM, Dixon CE, Shear DA, Dietrich WD, Schmid KE, et al. Approach to modeling, therapy evaluation, drug selection, and biomarker assessments for a multicenter pre-clinical drug screening consortium for acute therapies in severe traumatic brain injury: operation brain trauma therapy. J Neurotrauma. 2016;33:513–22.PubMedCrossRef

230.

Maas AIR, Menon DK, Steyerberg EW, Citerio G, Lecky F, Manley GT, et al. Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI): a prospective longitudinal observational study. Neurosurgery. 2015;76:67–80.PubMedCrossRef

Titel: A Precision Medicine Approach to Cerebral Edema and Intracranial Hypertension after Severe Traumatic Brain Injury: Quo Vadis?
verfasst von: Ruchira M. Jha
Patrick M. Kochanek
Publikationsdatum: 01.12.2018
Verlag: Springer US
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 12/2018
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-018-0912-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2018

Pharmacokinetic Considerations with the Use of Antiepileptic Drugs in Patients with HIV and Organ Transplants

Management of Blunt Cerebrovascular Injury

The Impact of Interictal Discharges on Performance

Closure of Patent Foramen Ovale and Cryptogenic Stroke: Unresolved Issues

Novel Imaging Biomarkers for Huntington’s Disease and Other Hereditary Choreas